CYNK-001

CYNK-001 Uses, Dosage, Side Effects, Food Interaction and all others data.

CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

Trade Name CYNK-001
Generic CYNK-001
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
CYNK-001
CYNK-001

How CYNK-001 works

CYNK-001 has the potential to inhibit viral infection by killing host cells through indirect immune responses. CYNK-001 expresses NKG2D and DNAM-1 receptors in addition to cytotoxicity receptors NKp30, NKp44, and NKp46. These receptors bind to the ligands and antigens expressed on infected cells, and initiate the release of perforin and granzyme B from the NK cell to induce cell death. In addition to being investigated for the treatment of acute myeloid leukemia, multiple myeloma, and glioblastoma multiforme, CYNK-001 is also being investigated for treating COVID-19.

Innovators Monograph

You find simplified version here CYNK-001


*** Taking medicines without doctor's advice can cause long-term problems.
Share